REVB · Revelation Biosciences, Inc.
$1.14
+0.02 (+1.79%)
At close · Aug 7
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company does not anticipate that its current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that the Company's unaudited condensed financial statements for June 30, 2026 were issued, which raises substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$4.54M
Shares
3.98M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| George Tidmarsh, M.D., Ph.D. | Director | Resigned | 2025-05-28 |